Jobs
-
DPI developer PureIMS has announced the appointment of Jaap Wieling as Chief Executive Officer (CEO), succeeding Bram Van Dijck. According to his LinkedIn page, Wieling founded or co-founded several biopharm companies, including Bioralix, BiosanaPharma, and… Read more . . .
-
Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in… Read more . . .
-
Pfizer is paying Biohaven Pharmaceutical a total of $500 million upfront plus up to $740 million in potential milestone payments for the rights to market Biohaven’s rimegepant (Nurtec ODT) and zavegepant (BHV-3500) outside of the… Read more . . .
-
MannKind Corporation said that it has purchased an additional convertible note issued by Thirona Bio, and MannKind CEO Michael Castagna has joined the Thirona board of directors, extending a June 2021 deal between the two companies for… Read more . . .
-
Intranasal vaccine developer Intravacc and Leiden University Medical Center (LUMC) have announced a planned Phase 1/2 trial of LUMC’s Nanovac intranasal vaccine against coronaviruses, including SARS, MERS, and SARS-CoV-2. The trial is expected to begin… Read more . . .
-
Israeli biopharm SpliSense has announced that both the FDA and the EMA have granted orphan drug designation to the company’s SPL84-23-1 inhaled antisense oligonucleotide (ASO) for the treatment of cystic fibrosis associated with the 3849+10… Read more . . .
-
According to Iliad Biotechnologies, the FDA has granted Fast Track designation to Iliad’s BPZE1 live attenuated intranasal vaccine against pertussis (whooping cough), which is in Phase 2 development as a booster vaccine to prevent both… Read more . . .
-
US-based Ritedose Pharmaceuticals, a subsidiary of CDMO Ritedose Corporation, has announced the launch of generic unit dose budesonide inhalation suspension (0.5 mg/2 ml) packaged for use in hospitals. Also, at the end of December, the… Read more . . .
-
Pieris Pharmaceuticals said that part 1a of a clinical trial of PRS-060/AZD1402, a dry powder IL-4 receptor alpha inhibitor which the company is developing with AstraZeneca for the treatment of moderate-to-severe asthma, has been completed.… Read more . . .
-
According to Liquidia Corporation, United Therapeutics has agreed to a court judgment finding that Liquidia did not infringe United Therapeutic’s US Patent No. 9,604,901. In October 2021, an inter partes review by the US Patent Trial and Appeal… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland